Northeast Financial Consultants Inc Bio N Tech Se Transaction History

Northeast Financial Consultants Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$123.25 - $186.24 $4,067 - $6,145	33 Added 1.69%	1,989 $297,000
Q1 2022 May 12, 2022	SELL	$126.25 - $231.85 $753,586 - $1.38 Million	-5,969 Reduced 75.32%	1,956 $334,000
Q4 2021 Feb 11, 2022	SELL	$216.64 - $362.52 $270,800 - $453,150	-1,250 Reduced 13.62%	7,925 $2.04 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $263,590 - $572,454	1,280 Added 16.21%	9,175 $2.51 Million
Q4 2020 Feb 12, 2021	SELL	$72.71 - $129.54 $23,848 - $42,489	-328 Reduced 3.99%	7,895 $644,000
Q3 2020 Oct 29, 2020	BUY	$57.81 - $104.17 $295,698 - $532,829	5,115 Added 164.58%	8,223 $574,000
Q2 2020 Jul 30, 2020	BUY	$38.58 - $66.74 $119,906 - $207,427	3,108 New	3,108 $207,000

356

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $26.3B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Northeast Financial Consultants Inc, based on Form 13F filings with the SEC.

Stay updated on Northeast Financial Consultants Inc with notifications on news.